Related Experiment Video
Updated: Feb 4, 2026

Author Spotlight: A Personalized Approach Towards Investigating Alzheimer's Disease Using an In Vitro Blood-Brain Barrier Model
Published on: October 20, 2023
Utilizing microphysiological systems and induced pluripotent stem cells for disease modeling: a case study for blood
Kristin M Fabre1, Louise Delsing2, Ryan Hicks3
1Microphysiological Systems Center of Excellence, Drug Safety & Metabolism, IMED Biotech Unit, AstraZeneca, Waltham, MA, United States.
Abstract:
Microphysiological systems (MPS) may be able to provide the pharmaceutical industry models that can reflect human physiological responses to improve drug discovery and translational outcomes. With lack of efficacy being the primary cause for drug attrition, developing MPS disease models would help researchers identify novel targets, study mechanisms in more physiologically-relevant depth, screen for novel biomarkers and test/optimize various therapeutics (small molecules, nanoparticles and biologics). Furthermore, with advances in inducible pluripotent stem cell technology (iPSC), pharmaceutical companies can access cells from patients to help recreate specific disease phenotypes in MPS platforms. Combining iPSC and MPS technologies will contribute to our understanding of the complexities of neurodegenerative diseases and of the blood brain barrier (BBB) leading to development of enhanced therapeutics.
More Related Videos
09:23Improved Method for the Establishment of an In Vitro Blood-Brain Barrier Model Based on Porcine Brain Endothelial Cells
Published on: September 24, 2017
06:20Author Spotlight: Developing a Unique Modular Microphysiological System to Mimic Human Barrier Tissue
Published on: February 16, 2024
Related Concept Videos
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells
Somatic...
The Blood-brain Barrier
Embryonic Stem Cells
Pharmaceutical Equivalents
Functional Brain Systems: Limbic System